AEON Biopharma Inc. (AEON)
0.40
0.00 (0.03%)
At close: Apr 17, 2025, 10:21 AM
0.03% (1D)
| Bid | 0.38 |
| Market Cap | 4.18M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | 42.01M |
| EPS (ttm) | 5250.96 |
| PE Ratio (ttm) | n/a |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.4 |
| Volume | 102,846 |
| Avg. Volume (20D) | 3,166,673 |
| Open | 0.41 |
| Previous Close | 0.40 |
| Day's Range | 0.38 - 0.41 |
| 52-Week Range | 0.38 - 489.60 |
| Beta | 0.35 |
About AEON
AEON Biopharma, Inc., a biopharmaceutical company, focuses on the development botulinum toxins for the treatment of debilitating medical conditions. It also develops 900 kDabotulinum toxin complex, ABP-450, for migraine, cervical dystonia, and gastroparesis. The company was formerly known as ALPHAEON Corporation and changed its name to AEON Biopharma, Inc. in December 2019. AEON Biopharma, Inc. was incorporated in 2012 and is headquartered in New...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2023
Employees 5
Stock Exchange NASDAQ
Ticker Symbol AEON
Website http://www.aeonbiopharma.com
Analyst Forecast
According to 1 analyst ratings, the average rating for AEON stock is "Buy." The 12-month stock price forecast is $360, which is an increase of 90534.44% from the latest price.
Stock Forecasts1 month ago
-43.29%
AEON Biopharma shares are trading lower after the ...
Unlock content with
Pro Subscription
3 months ago
-63.09%
AEON Biopharma shares are trading lower after the company announced the pricing of a $20 million offering of 40 million units at $0.50 per unit.
